AstraZeneca Czech Republic is a subsidiary of the international pharmaceutical behemoth known as AstraZeneca. It markets products such as heartburn reliever Nexium, local anesthetic Xylocaine, and endometriosis treatment Zoladex in the Czech Republic. It also conducts clinical trials on potential drug candidates in other parts of Central and Eastern Europe, such as Bulgaria, Hungary, Poland, Romania, and Slovenia. It focuses its research efforts primarily on the medical fields of gastroenterology, gynecology, and oncology, as well as bone and joint, cardiovascular, infectious, and respiratory diseases.

Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate dutogliptin is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and certain types of cancer. The biotechnology firm's drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. The company is owned by a number of private investors.

Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. The company markets and sells its products through in-house sales agents and distributors. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.

Cipla was founded as The Chemical, Industrial, & Pharmaceutical Laboratories by Khwaja Abdul Hamied in 1935; the founder's sons now head the company. Cipla is a market-leading medicine maker in India. The company has roughly 5,500 pharmaceutical products. Some are sold domestically, while the rest reach international markets in some 170 countries. It offers prescription drugs for all kinds of ailments -- arthritis, cancer, depression -- as well as over-the-counter drugs for colds, oral hygiene, and skin care. Cipla leads the domestic retail pharmaceutical market. The firm also makes bulk drugs, agrochemicals, and animal products. It has eight manufacturing plants located throughout the country.

RegeneRx Biopharmaceuticals was founded in 1982 and is headquartered in Rockville, Maryland. RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of novel molecules to promote tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tb4), a 43 amino acid peptide. Its product candidates in clinical development include RGN-137, a topically applied gel for chronic dermal wounds; RGN-259, a sterile topical eye drop for ophthalmic wounds; and RGN-352, a parenteral formulation for the treatment of patients with an acute myocardial infarction, or heart attack. Its pre-clinical development product includes RGN-457, an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases. The company has a strategic partnership with Defiante Farmaceutica L.d.a. for the development and marketing of RGN-137, and certain indications relating to RGN-352 primarily in Europe.

TopoTarget A/S company develops and markets anti-cancer drugs, as well as therapies for cancer-related conditions. Its portfolio includes preclinical candidates, drugs in clinical development, and marketed products. Its Savene therapy is sold in Europe and is a detoxifying drug which limits tissue damage after accidental exposure to certain chemotherapy agents; the drug is also marketed as Totect in the US. Founded in 2000, TopoTarget works with academic and commercial development partners in the US and Europe. Its biopharmaceutical candidates aim to fight cancers such as lymphoma, melanoma, and ovarian, breast, and neck cancers.

Althea Technologies provides services that help drug developers speed up the drug discovery and testing process, as well as reduce risks and costs associated with research and development efforts. Founded in 1998 by co-chairs Francois Ferre and Magda Marquet -- who hold Ph.D.s in molecular oncology and biochemical engineering -- the company assists in the development process from discovery through testing, regulatory support, and contract manufacturing stages. Services include gene expression analysis, protein production, and therapeutic and vaccine product manufacturing for clinical trials.

Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

Banner Pharmacaps, Inc., a drug delivery and specialty pharmaceutical company, engages in the research, development, and manufacture of oral dosage forms for the pharmaceutical health care industry. It develops drug delivery systems and patented technologies, including Soflet Gelcaps, a technology that enrobes tablets with a gelatin or non-animal film; LiquiSoftT Chewable Liquid-Filled Softgels, which is a chewable gel dosage form suitable for pediatric populations; Chewel, a soft chewable gelatin dosage form for pediatric populations; EnteriCare, which are enteric softgels; Versatrol, which is a controlled release softgel technology; and EcoCaps, which are non-animal softgels. It serves pharmaceutical and biotechnology, and consumer healthcare markets. The company was founded in 1994 and is headquartered in High Point, North Carolina. It has drug manufacturing facilities in High Point, North Carolina; Tilburg, the Netherlands; Olds, Canada; and Mexico City, Mexico. It has locations in Mexico, Europe, the Asia/Pacific, the United States, and Canada. Banner Pharmacaps, Inc. operates as a subsidiary of VION N.V.

Arnet Pharmaceutical manufactures private-label nutritional supplements. Arnet Pharmaceutical Corp. products range from daily vitamins and herbal extracts to minerals and amino acids. The company's capabilities include making tablet, capsule, powder, and chewable products. As a contract manufacturer, Arnet will work from customer-provided formulations or formulate products themselves. It also produces blended products such as Osteoporex, a calcium blend to address osteoporosis, and Gluthatione, an antioxidant supplement to increases energy and reduces stress. Founded in 1972, Arnet's customers span across more than 50 countries.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.